Limited evidence of pseudoprogression following immune checkpoint inhibitor (ICI) therapy in glioblastoma
"Pseudoprogression" following immune checkpoint inhibitors (ICI) in glioblastoma is often considered in case of radiographic progression. To better characterize the frequency of this phenomenon in glioblastoma, we reviewed the imaging response characteristics of a total of 55 patients treated with ICI in the setting of recurrent (<i>n</i> = 45) or newly diagnosed (<i>n</i> = 10) disease. There was no evidence of pseudoprogression related to ICI-monotherapy in the entire cohort.
Authors
- John Yohan Rhee (ORCID: https://orcid.org/0000-0002-2081-5667)
- Michael Parsons (ORCID: https://orcid.org/0000-0001-8619-9564)
- Thomas Nelson (ORCID: https://orcid.org/0000-0003-3942-5527)
- Juan Pablo Ospina Botero
- Jörg Dietrich (ORCID: https://orcid.org/0000-0001-8291-0136)
- Kun Song (ORCID: https://orcid.org/0000-0003-3822-2891)
- Elizabeth Robins Gerstner (ORCID: https://orcid.org/0000-0003-2382-3838)
Institutions
- Palo Alto University (US)
- University of California, San Francisco (US)
- Massachusetts General Hospital (US)
- Center for Neuro-Oncology (US)
- Dana-Farber Cancer Institute (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1093/noajnl/vdaf232
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00